Luye Pharma Group Ltd. Annual Report 2025 – Key Financials, Strategic Updates, and Price-Sensitive Information

Luye Pharma Group Ltd. (“the Company”, “the Group”) has released its audited consolidated financial statements and key management discussion for the year ended 31 December 2025. This article provides a comprehensive analysis for shareholders and potential investors, focusing on developments that could impact share value.

1. Financial Performance Highlights

• Revenue Growth: The Group achieved revenue of RMB 6,308.4 million for 2025, up 4.1% from RMB 6,061.4 million in 2024, signifying solid topline growth in a competitive environment.
• Net Profit: Net profit attributable to owners of the parent increased to RMB 618.7 million, a robust 31% increase from RMB 471.9 million in 2024. Overall group net profit was RMB 705.7 million, up 9.4% year-on-year.
• Gross Profit: Gross profit reached RMB 4,162.6 million (2024: RMB 4,044.2 million), maintaining a strong margin profile despite cost pressures.
• Other Income and Gains: A significant increase to RMB 472.4 million (up 31.2% from RMB 360 million), mainly due to higher fair value gains on derivatives and net foreign exchange gains, offsetting lower government grants.
• Selling and Distribution Expenses: Slight increase to RMB 1,826.2 million (+0.5%), while as a percentage of revenue, decreased to 28.9% from 30.0%.
• Administrative Expenses: Rose to RMB 679.6 million (2024: RMB 582 million), reflecting higher staff costs and general operational expenses.
• Finance Costs: Increased sharply to RMB 686.6 million (2024: RMB 561.8 million), reflecting the financing structure and new bond issues.
• Cash & Liquidity: Net current assets surged to RMB 5,296.9 million (2024: RMB 2,539.0 million); current ratio improved to 1.53 (2024: 1.24).
• Borrowings: Total interest-bearing loans and borrowings at RMB 8,352.0 million (RMB 8,294.4 million in 2024), with RMB 6,694.1 million due within one year.

2. Capital Market Activities – Convertible Bonds

• 2023 Convertible Bonds: US\$180 million issued at 6.25% interest, convertible at HK\$4.88 per share, maturing July 2028. Early redemption option in July 2026. Fair value of liability and equity components separated in financials.
• 2024 Convertible Bonds: US\$150 million issued at 5.85% interest (in two tranches), convertible at HK\$3.672 per share, maturing October 2025. Net proceeds of HK\$1,148.5 million used for refinancing existing debt, R&D, and general corporate purposes. All proceeds fully utilized as per disclosures.
• Conversion Activity: During 2025, US\$110 million of convertible bonds were converted into 232,845,310 ordinary shares at HK\$3.672 per share, increasing issued capital and potentially diluting EPS going forward.

3. Exchangeable Preference Shares – Potential Impact on Boan Biotech

• On November 21, 2025, 1.5 million exchangeable preference shares were issued to Bluebell Asset Holding Ltd. for US\$150 million. These shares are non-voting, pay 4.75% annual dividends, and are exchangeable into shares of Boan Biotech (a subsidiary) at HK\$11.718/share.
• These preference shares can be exchanged any time within 60 months or are mandatorily exchanged at expiry, or redeemed by the issuer after 6 months at 1.35x the exchange price. The fair value of these instruments is sensitive to Boan Biotech’s valuation and market perceptions.
• Price-Sensitive Note: The issuance and potential conversion of these preference shares could significantly impact Boan Biotech’s shareholding structure and valuation, and hence the Group’s consolidated results.

4. Dividends and Capital Management

• No Dividends Declared: The Board did not recommend any interim or final dividends for 2025, highlighting a preference for reinvestment and maintaining liquidity for growth and debt management.
• Gearing Ratio: Improved to 45% from 53% as equity increased, reflecting a healthier balance sheet, though absolute borrowings remain high.

5. Significant Investments & Financial Assets

• The Group held financial assets at fair value through profit or loss totaling RMB 3,796.1 million at 2025 year-end (up from RMB 2,122.6 million in 2024). This includes unlisted wealth management products and investments in private funds, with fair values closely monitored for market risk.
• No single investment exceeded 5% of total assets, reducing concentration risk.

6. Risk Management & Governance

• The company identifies market risk, operational risk, investment risk, and manpower retention as key risks, with detailed internal controls, audit, and governance procedures in place.
• Foreign exchange and interest rate exposures are actively managed. Sensitivity analysis indicates that a 5% movement in RMB/USD or USD/EUR could have a material impact on profit and equity.

7. ESG and Compliance

• The ESG Committee, with independent directors, coordinates environmental, social, and governance strategies. The 2025 ESG Report is available online.
• No change to the Company’s Bye-laws during the year. Corporate governance remains a focus, with all code provisions complied except as disclosed.

8. Other Notable Items

• Share Capital: Issued shares increased to 3,994,515,953 by year-end 2025, primarily due to bond conversions. This has dilution implications for existing shareholders.
• Audit: Ernst & Young remains as auditor, with RMB 15.8 million paid for audit services, plus RMB 1.47 million for transfer pricing advisory.
• No Share Buybacks: No purchase, sale, or redemption of listed securities during the year.
• Public Float: The Company confirms sufficient public float for its shares under Listing Rules.
• Events After Reporting Period: No significant events requiring disclosure post year-end.

Potential Price-Sensitive Issues for Investors

• Convertible Bonds & Preference Shares: Ongoing conversions and exchangeable shares could dilute existing shareholders, impact EPS, and alter control of key subsidiaries (Boan Biotech).
• Profit Growth vs. Dividend Policy: The robust profit growth in 2025 did not translate into dividends, which may disappoint income-focused investors but supports capital growth and debt management.
• Leverage & Liquidity: Improved gearing and liquidity position are positive, yet high absolute debt levels and finance costs warrant close monitoring.
• Exposure to Market Risks: The Group remains exposed to currency and interest rate volatility, which may impact future earnings.

Conclusion

Luye Pharma Group Ltd. delivered strong financial growth in 2025, executed significant capital market transactions, and maintained prudent risk management and governance. However, investors should closely monitor the implications of ongoing convertible bond conversions, exchangeable preference shares, and the Group’s high leverage. These factors, combined with the absence of dividends and ongoing investment in R&D and market expansion, could drive significant share price movements and should be carefully considered in investment decisions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold securities of Luye Pharma Group Ltd. or its affiliates. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The author accepts no liability for any loss arising from the use of this information.

View LUYE PHARMA Historical chart here